

Ifw



Attorney Docket No. SURR.113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	ALLISON)	
SERIAL NO.:	10/632,694)	EXAMINER: SNEDDEN, S.
FILED:	AUGUST 1, 2003)	ART UNIT: 1653
TITLE:	MODIFIED ANNEXIN PROTEINS AND METHODS FOR TREATING VASO-OCCLUSIVE SICKLE-CELL DISEASE)	CONFIRMATION NO.: 3876

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

This Statement is accompanied by a check for \$180 in accordance with 37 CFR §§1.97(c) and 1.17(p). The undersigned hereby authorizes the charging of any deficiency of fees submitted herewith to Deposit Account No. 19-5117.

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 8/4/04

08/06/2004 CNGUYEN 00000043 10632694

01 FC:1806


180.00 OP

Signature: Tasha L. Cove
Name: Tasha L. Cove

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: August 4, 2004



Darla G. Yoerg, #48,053
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

cc: W. Leschensky
S:\CLIENT FOLDERS\SURROMED\113\IDS02.DOC




FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 2	ATTY. DOCKET NO. SURRE.113	SERIAL NO. 10632694
	APPLICANT ALLISON	
	FILING DATE 8/1/03	GROUP 1653

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	5612460	3/18/97	ZALIPSKY ET AL.			
	AB	6358508	3/19/02	NI ET AL.			
	AC	6171577	1/9/01	RENO ET AL.			
	AD	5608060	3/4/97	AXWORTHY ET AL.			
	AE	4507229	3/26/85	BOHN			
	AF	5097019	3/17/92	LOBERMANN ET AL.			
	AG	4736018	4/5/88	REUTELINGSPERGER			
	AH	5066787	11/19/91	REUTELINGSPERGER			
	AI	5066788	11/19/91	REUTELINGSPERGER			
	AJ	5225537	7/6/93	FOSTER			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRAN S?
	AK	EP 0 318 703	7/6/89	EP			
	AL	WO9107187	5/16/91	PCT			
	AM	WO9919470	4/22/99	PCT			
	AN	WO0002587	1/20/00	PCT			
	AO	WO02087498	11/7/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AP	Chap et al., Biochem Biophys Res Commun 1988, 150:972-978.
	AQ	Funakoshi et al., Biochemistry 1987, 26:5572-5578.
	AR	Grundmann et al., Behring Inst Mitt 1988, 82:59-67.
	AS	Grundmann et al., Proc Natl Acad Sci USA 1988, 85:3708-3712.
	AT	Iwasaki et al., J Biochem (Tokyo) 1987, 102:1261-1273.
	AU	Kaplan et al., J Biol Chem 1988, 263:8037-8043.
	AV	Maurer-Fogy et al., Eur J Biochem 1988, 174:585-592.
	AW	Nakao et al., Chem Pharm Bull (Tokyo) 1990, 38:1957-1960.
	AX	Reutelingsperger et al., Eur J Biochem 1985, 151:625-629.
	AY	Reutelingsperger et al., Eur J Biochem 1988, 173:171-178.
	AZ	Romisch et al., Biochem J 1990, 272:223-229.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 2	ATTY. DOCKET NO. SURR.113	SERIAL NO. 10632694
	APPLICANT ALLISON	
	FILING DATE 8/1/03	GROUP 1653

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	BA	4732891	3/22/88	MAKI ET AL.			
	BB	5591633	1/7/91	SAINO ET AL.			
	BC	5290915	3/1/94	NAKAO ET AL.			
	BD	5296467	3/22/94	REUTELINGSPERGER			
	BE	4179337	12/18/79	DAVIS ET AL.			
	BF	4002531	1/11/77	ROYER			
	BG	6242570	6/5/01	SYTKOWSKI			
	BH	4937324	6/26/90	FUJIKAWA ET AL.			
	BI						
	BJ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	BK	Rothhut et al., Biochem J 1989, 263:929-935
	BL	Sytkowski et al. (1998) Proc Natl Acad Sci Usa 95:1184-1188
	BM	Pepinsky et al. (1988) J Biol Chem 263(22):10799-10811
	BN	Kassam et al. (1998) J Biol Chem 273(8):4790-4799
	BO	Zanma et al. (1991) J Biochem 110(6):868-872
	BP	Delgado et al. (1992) Critical Rev In Therapeutic Drug Carrier Systems 9(3/4):249-304
	BQ	Stueber et al. (1995) Peptide Research 8(2):78-85
	BR	Database WPI, Section Ch, Weed 200036, Derwent Publications Ltd, London, Class B04, Shanghai Inst Biochem Chinese Acad (2000) Abstract
	BS	Schlaepfer et al. (1987) Proc. Natl. Acad. Sci. USA 84:6078-6082
	BT	
	BU	
	BV	
	BW	
	BX	
	BY	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.		